Ariceum Therapeutics Launches with €25M Series A
Find out what sets Ariceum Therapetutics apart within the radiopharmaceutical arena in this insightful interview with its CEO Manfred Rüdiger and Tyler Patchen of Endpoint News
Find out what sets Ariceum Therapetutics apart within the radiopharmaceutical arena in this insightful interview with its CEO Manfred Rüdiger and Tyler Patchen of Endpoint News
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Copenhagen, Denmark, May 3, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the […]
New data highlight the strength and versatility of Leucid’s proprietary, next-generation technology pCAR has now achieved proof-of-concept across a range of co-stimulatory domains, binders, targets and target combinations in pre-clinical liquid and solid tumour cell lines/models John Maher has been an early pioneer of CAR T-cell immunotherapy with a focus on solid tumours London, UK […]
Inobrodib is the first drug to target p300/CBP, a new way to treat specific cancers. Following a successful Phase I campaign, new funding will be used to progress clinical development towards to pivotal registration trials. Cambridge, UK, 26 January 2022 – CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat […]